Physician profile
Peter J Campbell
NPI 1386640647
$4,621.43
in general payments reported to CMS, 2019-2025
26 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,684 · 2020: $250 · 2021: $147 · 2022: $531 · 2023: $506 · 2024: $248 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,897.00 | 2019 | |
| Medtronic USA, INC. | $526.22 | 2019 | |
| Abbott Laboratories | $469.43 | 2021-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $250.00 | 2020 | |
| Dexcom, INC. | $248.79 | 2019-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $197.54 | 2019-2025 | Wegovy, Sogroya, Norditropin |
| Amgen INC. | $161.72 | 2019-2025 | Tepezza, Prolia, Evenity |
| Ultragenyx Pharmaceutical INC. | $103.61 | 2022-2023 | |
| Intuitive Surgical, INC. | $99.52 | 2022 | |
| Ascendis Pharma Endocrinology INC | $88.88 | 2025 | Yorvipath |
| Pfizer INC. | $87.80 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $72.90 | 2023 | |
| Nevro Corp. | $67.27 | 2021-2023 | Senza |
| Abbvie INC. | $57.51 | 2021-2023 | Synthroid |
| Horizon Therapeutics Plc | $45.14 | 2023 | Tepezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Senseonics, Incorporated | $45.00 | 2019 | |
| Lifescan, INC. | $41.31 | 2019 | |
| Gilead Sciences, INC. | $34.22 | 2019 | |
| Chiesi USA, INC. | $21.39 | 2025 | Mycapssa |
| Astellas Pharma US INC | $20.86 | 2023 | Veozah |
| Cequr Corporation | $16.09 | 2024 | Cequr Simplicity |
| Echosens North America, INC. | $15.79 | 2025 | Fibroscan |
| Xeris Pharmaceuticals, INC. | $14.05 | 2021 | |
| Amarin Pharma, INC. | $13.81 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.62 | 2022 | |
| Esperion Therapeutics, INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.